Holen Sie sich die Stockscreener-App
3.06
1.66%
0.05
Handel nachbörslich:
2.97
-0.09
-2.94%
Schlusskurs vom Vortag:
$3.01
Offen:
$3.02
24-Stunden-Volumen:
316.85K
Relative Volume:
0.86
Marktkapitalisierung:
$161.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-197.68M
KGV:
-0.8138
EPS:
-3.76
Netto-Cashflow:
$-158.88M
1W Leistung:
-4.67%
1M Leistung:
-23.69%
6M Leistung:
+15.04%
1J Leistung:
-58.93%
1-Tages-Spanne:
$2.99
$3.14
1-Wochen-Bereich:
$2.9701
$3.59
52-Wochen-Spanne:
$2.185
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1200 PAGE MILL RD, PALO ALTO, CA
Vergleichen Sie KOD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
3.06 | 161.03M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2023-12-11 | Fortgesetzt | Goldman | Sell |
| 2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-15 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-03 | Eingeleitet | Goldman | Buy |
| 2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Eingeleitet | SunTrust | Buy |
| 2020-01-08 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-10-29 | Eingeleitet | Barclays | Overweight |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
| 2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
Kodiak Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KODIAK SCIENCES Earnings Results: $KOD Reports Quarterly Earnings - Nasdaq
Kodiak Sciences Cuts Losses by 26%, Advances Two Phase 3 Trials with $168M War Chest - StockTitan
Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? - Insider Monkey
Diabetic Macular Edema Pipeline 2025: Therapies Under - openPR
Kodiak Sciences Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Critical Contrast: Metagenomi (NASDAQ:MGX) & Kodiak Sciences (NASDAQ:KOD) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Retinal Vein Occlusion Clinical and Non-Clinical Studies, Key - openPR
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate - MSN
Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Why Palantir (PLTR) Stock Is Up Today - The Globe and Mail
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy - Marketscreener.com
Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial - TipRanks
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
CDC To Study Vaccines and Autism, Despite Much Research Showing No Link - 69News WFMZ-TV
Clinical Trial Success: Kodiak Enrolls 250+ Patients for Novel Diabetic Eye Drug - StockTitan
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Yahoo Finance
Kodiak Sciences’ Anti-VEGF Could Win Nicely On Retinal Disorders (NASDAQ:KOD) - Seeking Alpha
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Large Increase in Short Interest - MarketBeat
Elisa Oyj (OTCMKTS:ELMUF) Short Interest Update - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Growth in Short Interest - Defense World
166,843 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Bought by Peapod Lane Capital LLC - MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
SG Americas Securities LLC Has $209,000 Stock Holdings in Levi Strauss & Co. (NYSE:LEVI) - American Banking and Market News
SG Americas Securities LLC Has $206,000 Stake in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Diabetic Retinopathy Market on Track for Major Expansion by 2034, According to DelveInsight | Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim - Barchart
Diabetic Retinopathy Market on Track for Major Expansion - openPR
Quarterly Dosing Breakthrough: Kodiak's New Glaucoma Treatment Targets Root Causes - StockTitan
Kodiak Sciences Inc.'s (NASDAQ:KOD) institutional investors lost 23% over the past week but have profited from longer-term gains - Simply Wall St
JPMorgan Chase & Co. Purchases 30,735 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
NASA's 2 stuck astronauts take their first spacewalk together - 69News WFMZ-TV
Polaris, General Motors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Age-related Macular Degeneration Treatment Market Size in the 7MM was ~USD 9,840 million in 2023,is further expected to grow by 2034 | DelveInsight - The Globe and Mail
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Barclays PLC - Defense World
Gran Tierra Energy Inc. (NYSE:GTE) Shares Bought by Barclays PLC - Defense World
Short Interest in Kodiak Sciences Inc. (NASDAQ:KOD) Rises By 8.1% - Defense World
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update - MarketBeat
Jane Street Group LLC Has $90,000 Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing - MSN
Why These 24 Stocks Are Skyrocketing - Insider Monkey
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates - MSN
Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type - GlobeNewswire Inc.
Geode Capital Management LLC Acquires 12,783 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Barclays PLC - Defense World
Kodiak Sciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.46%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):